OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research
IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program. By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely medical centers, universities, and pharmaceutical companies dedicated to advancing the scientific and clinical knowledge of gynecologic cancers.
OvaGene's mission to improve the quality of life and survival for gynecologic cancer patients is further enhanced by joining this select group. The Industry Collaboration Team has a limited membership and OvaGene is honored to have been given an opportunity to become a member. By joining the ICT program, OvaGene will gain direct access to oncology leaders and key decision makers in the field gynecologic oncology. This will facilitate direct communication with the cancer treating physicians about OvaGene's products and diagnostic research capabilities. The valuable feedback provided can help accelerate the development of OvaGene's product pipeline by allowing the company to identify and address unmet clinical needs.
"We are very pleased to be an ICT member," said William Ricketts, Ph.D., Chief Scientific Officer for OvaGene. "The GOG has one of the largest archived and annotated gynecologic tumor banks. It is a privilege to be given the opportunity to collaborate with the GOG as a member of the ICT and potentially on studies focused to discover and validate new molecular diagnostics. This will help us bring cl